Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19
Loading...
Access rights
openAccess
publishedVersion
URL
Journal Title
Journal ISSN
Volume Title
A2 Katsausartikkeli tieteellisessä aikakauslehdessä
This publication is imported from Aalto University research portal.
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
Other link related to publication (opens in new window)
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
Other link related to publication (opens in new window)
Date
2021-07
Department
Major/Subject
Mcode
Degree programme
Language
en
Pages
9
Series
Heliyon, Volume 7, issue 7
Abstract
The contagiosity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has startled mankind and has brought our lives to a standstill. The treatment focused mainly on repurposed immunomodulatory and antiviral agents along with the availability of a few vaccines for prophylaxis to vanquish COVID-19. This seemingly mandates a deeper understanding of the disease pathogenesis. This necessitates a plausible extrapolation of cell-based therapy to COVID-19 and is regarded equivalently significant. Recently, correlative pieces of clinical evidence reported a robust decline in lymphocyte count in severe COVID-19 patients that suggest dysregulated immune responses as a key element contributing to the pathophysiological alterations. The large granular lymphocytes also known as natural killer (NK) cells play a heterogeneous role in biological functioning wherein their frontline action defends the body against a wide array of infections and tumors. They prominently play a critical role in viral clearance and executing immuno-modulatory activities. Accumulated clinical evidence demonstrate a decrease in the number of NK cells in circulation with or without phenotypical exhaustion. These plausibly contribute to the progression of pulmonary inflammation in COVID-19 pneumonia and result in acute lung injury. In this review, we have outlined the present understanding of the immunological response of NK cells in COVID-19 infection. We have also discussed the possible use of these powerful biological cells as a therapeutic agent in view of preventing immunological harms of SARS-CoV-2 and the current challenges in advocating NK cell therapy for the same.Description
Funding Information: We thank Dr. Prajwal GS, Junior Resident of Orthopedics, JJM Medical College, Davangere, Karnataka, India for the literature search regarding COVID-19. Publisher Copyright: © 2021
Keywords
COVID-19, Cytokines, Natural killer cells, Pulmonary inflammation, SARS-CoV-2
Other note
Citation
Jeyaraman, M, Muthu, S, Bapat, A, Jain, R, Sushmitha, E S, Gulati, A, Channaiah Anudeep, T, Dilip, S J, Jha, N K, Kumar, D, Kesari, K K, Ojha, S, Dholpuria, S, Gupta, G, Dureja, H, Chellappan, D K, Singh, S K, Dua, K & Jha, S K 2021, ' Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19 ', Heliyon, vol. 7, no. 7, 07635 . https://doi.org/10.1016/j.heliyon.2021.e07635